IGC Pharma’s Advisor and Inventor of Drug Candidate TGR-63 Receives Award
Retrieved on:
Monday, June 5, 2023
Cannabis, Alternative Medicine, Natural Resources, Health, Pharmaceutical, Translation, Therapy, Jawaharlal Nehru Centre for Advanced Scientific Research, Earth science, JNCASR, Amnesia, Government, Amyloid, DST, IGC, TDB, Mouse, Department of Science and Technology (India), NYSE, Microprocessor, National Technology Business Centre, Pharmaceutical industry, Science
IGC Pharma, Inc (NYSE American: IGC) ("IGC" or the "Company"), today announced that its Advisor, Professor T. Govindaraju the inventor of the investigational Alzheimer’s drug candidate, TGR-63, received the Government of India-instituted National Technology Award (Translational Research) for “Outstanding Contribution in Commercializing Innovative Indigenous Technologies” from the Minister of State for Science and Technology and Earth Sciences.
Key Points:
- IGC Pharma, Inc (NYSE American: IGC) ("IGC" or the "Company"), today announced that its Advisor, Professor T. Govindaraju the inventor of the investigational Alzheimer’s drug candidate, TGR-63, received the Government of India-instituted National Technology Award (Translational Research) for “Outstanding Contribution in Commercializing Innovative Indigenous Technologies” from the Minister of State for Science and Technology and Earth Sciences.
- IGC Pharma, Inc., acquired exclusive rights to TGR-63 from researchers at India-based Jawaharlal Nehru Centre for Advanced Scientific Research (JNCASR) that created the TGR-63 molecule.
- Pre-clinical testing demonstrates that TGR-63 holds the potential to ameliorate amyloid plaque a key hallmark of Alzheimer’s disease.
- The Department of Science and Technology (DST)-Technology Development Board (TDB), Government of India recognized Professor Govindaraju with the prestigious award on May 14, 2023.